Form 4: Cabaletta Bio Director Catherine Bollard Reports Stock Option Repricing

Catherine Bollard, a director at Cabaletta Bio, reported a repricing of stock options effective May 19, 2025, according to a Form 4 filing with the SEC.

Summary

• Catherine Bollard, a director of Cabaletta Bio, Inc., filed a Form 4 with the SEC on May 19, 2025.
• The filing reports changes in beneficial ownership due to a stock option repricing.
• The repricing, approved by the Issuer's board of directors on May 15, 2025, became effective on May 19, 2025.
• The exercise price of certain stock options was adjusted to $1.92 per share, representing the fair market value on the repricing date.
• The filing details the acquisition and disposal of derivative securities (stock options) as a result of the repricing.
• The repriced stock options will revert to their original exercise price if exercised during the Retention Period, which ends one year after the Repricing Date, upon a Sale Event, or termination of service due to death or disability.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option repricing, which is neither particularly positive nor negative. The sentiment is neutral.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the stock option repricing and vesting schedules.

Industry Context

Stock option repricing is a mechanism companies use to re-incentivize employees or directors when the stock price has fallen below the option's exercise price. This can help retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, particularly in the biotechnology industry, where stock prices can be volatile.
• Companies like Amgen, Biogen, and Gilead Sciences also use stock options as part of their compensation packages.
• The specific terms of the repricing, such as the Retention Period, are company-specific and depend on their compensation philosophy.

Stakeholder Impact

• The stock option repricing may incentivize the director to work towards increasing shareholder value.
• Employees holding similar options may also be positively impacted by the repricing.

Key Dates

Keywords

Form 4, Stock Options, Repricing, Cabaletta Bio, Beneficial Ownership, Director, Catherine Bollard